Fei Lin

Fei Lin

Auto-generated profile, based on publicly available information

Fei Lin

Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YWYu-Peng Wu
Yu-Peng Wu
ZKZhi-Bin Ke
Zhi-Bin Ke
WZWen-Cai Zheng
Wen-Cai Zheng
YCYe-Hui Chen
Ye-Hui Chen
JZJun-Ming Zhu
Jun-Ming Zhu
NXNing Xu
Ning Xu
Expression of kinesin family member 18B (KIF18B), an ATPase with key roles in cell division, is deregulated in many cancers, but its involvement in prostate cancer (PCa) is unclear. Here, we investigated the expression and function of KIF18B in human PCa specimens and cell lines using bioinformatics analyses, immunohistochemical and immunofluorescence microscopy, and RT-qPCR and western blot analyses. KIF18B was overexpressed in PCa specimens compared with paracancerous tissues and was associated with poorer disease-free survival. In vitro, KIF18B knockdown in PCa cell lines promoted cell proliferation, migration, and invasion, and inhibited cell apoptosis, while KIF18B overexpression had the opposite effects. In a mouse xenograft model, KIF18B overexpression accelerated and promoted the growth of PCa tumors. Bioinformatics analysis of control and KIF18B-overexpressing PCa cells showed that genes involved in the PI3K–AKT–mTOR signaling pathway were significantly enriched among the differentially expressed genes. Consistent with this observation, we found that KIF18B overexpression activates the PI3K–AKT–mTOR signaling pathway in PCa cells both in vitro and in vivo. Collectively, our results suggest that KIF18B plays a crucial role in PCa via activation of the PI3K–AKT–mTOR signaling pathway, and raise the possibility that KIF18B could have utility as a novel biomarker for PCa.

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ZKZhi-Bin Ke
Zhi-Bin Ke
SCShao-Hao Chen
Shao-Hao Chen
YCYe-Hui Chen
Ye-Hui Chen
YWYu-Peng Wu
Yu-Peng Wu
FLFei Lin
Fei Lin
YWYong Wei
Yong Wei
Background. Patients with brain metastases (BM) from renal cell carcinoma (RCC) were considered to experience a poor prognosis. However, there is little knowledge on the risk factors for BM from RCC at diagnosis. This study was aimed at exploring the risk factors for patients with BM from RCC and the interaction among these risk factors. Methods. A total of 38759 cases of RCC were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Risk factors for BM from RCC were evaluated by univariate and multivariate logistic regression analyses. Interaction effect between age and tumor size was tested. Results. There was a significant difference in univariate analysis, including T stage, tumor size, grades III and IV, lymph node metastasis, bone metastasis, liver metastasis, lung metastasis, and surgery. There was a significant difference in multivariate analysis, including age, T stage, tumor size < 10 cm, grade IV, lymph node metastasis, bone metastasis, lung metastasis, and surgery. Patients older than 70 had 0.653‐fold lower risk of developing BM compared with those younger than 70. Patients with tumor size ≥ 4 cm and <10 cm had higher risk of developing BM compared with those < 4 cm. The larger the tumor size, the higher the incidence of BM from RCC in those whose tumor size was less than 10 cm. An interaction test between the tumor size and age on brain metastasis was statistically significant in the crude analysis (P = 0.0114) and model II analysis (P = 0.0248) but not in model I analysis (P = 0.1136). Although age significantly affected the risk of BM from RCC, impact of age on the risk of developing BM from RCC was limited to patients with tumor size ≥ 7 cm. Conclusion. Both tumor size and age were independent risk factors for brain metastases in patients with RCC. The impact of age on the risk of developing BM from RCC was limited to patients with tumor size ≥ 7 cm. Patients with a larger tumor size and younger age might have the higher risk of developing BM at diagnosis of RCC.

8 May 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YWYiqiu Wang
Yiqiu Wang
JLJiayi Lu
Jiayi Lu
BLBohan Lin
Bohan Lin
JCJiayin Chen
Jiayin Chen
FLFei Lin
Fei Lin
NXNing Xu
Ning Xu
Clear-cell renal cell carcinoma (ccRCC) is a highly aggressive malignancy that originates in the kidney. It often exhibits a limited response or can be refractory to a wide range of anti-cancer therapies, including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors. Ferroptosis is a form of oxidative, iron-dependent cell death characterized by lipid peroxidation. Targeting ferroptosis may offer a promising alternative therapeutic strategy for cancer cells that are resistant to existing treatments. The impact of ferroptosis-related genes on the prognosis of ccRCC patients is still not fully understood. In this study, we identified 30 differentially expressed ferroptosis-related genes in ccRCC samples compared to normal tissues using data from The Cancer Genome Atlas (TCGA). Lasso regression analyses, along with Kaplan-Meier analysis, were conducted to identify genes associated with prognosis. Based on scRNA-seq and spatial transcriptome analysis, we identified specificity of MIOX in ccRCC. Furthermore, MIOX demonstrated the highest significance, highlighting its independent prognostic value as a single gene in ccRCC. Our findings suggest that MIOX could serve as potential targets for therapeutic interventions in ccRCC.

19 March 2026 in Cell Death & Disease
Verified
Journal Article
Open access
JCJia-Yin Chen
Jia-Yin Chen
YXYu-Ting Xue
Yu-Ting Xue
BLBin Lin
Bin Lin
XHXu-Yun Huang
Xu-Yun Huang
FLFei Lin
Fei Lin
NXNing Xu
Ning Xu
The resistance to radiotherapy of prostate cancer is driven by interactions within the tumor microenvironment, particularly between prostate cancer cells and tumor-associated macrophages, however the underlying mechanisms remain poorly understood. In this study, we found that STAT1 enhanced the transcription of critical glycolytic enzymes, leading to an increase in lactate secretion from prostate cancer cells. Then, the lactate was transported to macrophages via the MCT1 transporter, activating the NFκB1 pathway, which subsequently promoted macrophage polarization to the M2 phenotype and activated the transcription of MCP-1. MCP-1 was secreted from macrophages interacted with the CCR2 receptor on prostate cancer cells, thereby activating the JAK/STAT1 pathway, ultimately contributing to the progression of prostate cancer and its resistance to radiotherapy. Taken together, our findings identified a STAT1/lactate/NFκB1/MCP-1 positive feedback mechanism as a driver of prostate cancer progression and resistance to radiotherapy that functioned by interaction to macrophages, which could be potential therapeutic targets for the advanced prostate cancer.